Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed

6 November 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported third‑quarter 2025 results this morning (Nov. 6), highlighting sequential revenue growth, materially higher gross margins, and steady commercial momentum for its tumor‑infiltrating lymphocyte (TIL) therapy Amtagvi. Management also reaffirmed full‑year revenue guidance and flagged pipeline milestones led by encouraging lung‑cancer data for lifileucel. ^[1]

Q3 revenue ~$68M, up ~13% QoQ; gross margin 43%. The company cited improved execution and early benefits of cost optimization. Full‑year 2025 revenue guidance remains $250–$300M in Amtagvi’s first full calendar year on the market. ^[2]
Bottom line: Net loss of $91.3M (‑$0.25 per share). Revenue of $67.5M missed consensus, while EPS beat some estimates, according to Associated Press/Zacks summaries. ^[3]
Regulatory & pipeline: Interim IOV‑LUN‑202 data in nonsquamous NSCLC show an ~26% ORR with median duration of response not reached (>25 months), supporting plans to pursue regulatory pathways; more data are expected in 2026. ^[4]
Operations & access: >80 U.S. authorized treatment centers now active; distribution broadened via a specialty‑pharmacy agreement with InspiroGene by McKesson; average manufacturing turnaround ~32 days. ^[5]
Liquidity: Cash, equivalents, investments, and restricted cash ~$307M at Sept. 30; runway expected into Q2 2027 after recent cost actions. ^[6]
Compliance note: Iovance furnished its results and press release via an SEC Form 8‑K this morning. ^[7]

What Iovance announced (Nov. 6, 2025)

Revenue, margin, and guidance. Total product revenue grew to ~$68M in Q3 (Amtagvi ~$58M; Proleukin ~$10M). Gross margin expanded to 43% on improved execution and early cost‑savings. Management reaffirmed $250–$300M in 2025 revenue. ^[8]

Earnings snapshot. An AP/Automated Insights brief noted a net loss of $91.3M or ‑$0.25 per share on $67.5M in revenue, with EPS topping some forecasts but sales below Street expectations. ^[9]

Filing & webcast. The company filed an 8‑K with the press release and scheduled a conference call and webcast at 8:30 a.m. ET to review results and provide updates. ^[10]

Investor materials. Iovance also posted a fresh corporate presentation dated today, aligning with the Q3 update. ^[11]

Commercial execution: where growth is coming from

Treatment‑center footprint. Iovance says >80 U.S. authorized treatment centers (ATCs) are active across nearly 40 states, placing ~95% of eligible patients within a ~two‑hour drive. Expansion into community centers is expected to support earlier treatment and demand. ^[12]
Patient access & logistics. A new specialty‑pharmacy agreement with InspiroGene by McKesson is intended to broaden access. Meanwhile, manufacturing turnaround averages ~32 days from inbound tumor sample to shipment back to ATCs, with further operational initiatives underway. ^[13]
Global expansion.Health Canada approved Amtagvi in August 2025; Iovance anticipates potential approvals in the U.K. and Australia in 1H26 and in Switzerland in 2027, and is finalizing an EMA strategy. ^[14]

Pipeline update: lifileucel beyond melanoma

NSCLC (IOV‑LUN‑202). Interim Phase 2 monotherapy data in previously treated nonsquamous NSCLC reported an ~26% objective response rate with median DOR not reached after >25 months. The design has positive FDA feedback, and Iovance expects enrollment completion in 2026, targeting a supplemental BLA and a potential 2027 launch if successful. ^[15]
Broader development. Early readouts for endometrial cancer (IOV‑END‑201) are planned for early 2026; the TILVANCE‑301 combo trial (lifileucel + pembrolizumab) continues in frontline melanoma; next‑gen programs IOV‑4001 (PD‑1–inactivated TIL), IOV‑3001 (next‑gen IL‑2), and IOV‑5001 (inducible tethered IL‑12 TIL) are slated for updates through 2026. ^[16]

By the numbers (Q3 2025)

Revenue: ~$68M (Amtagvi ~$58M; Proleukin ~$10M) — up ~13% QoQ. ^[17]
Gross margin:43% (improved execution/cost optimization). ^[18]
Net loss / EPS:‑$91.3M / ‑$0.25; revenue $67.5M vs. lower‑Street consensus in AP brief. ^[19]
Cash & investments:~$307M (runway into Q2 2027). ^[20]

Market reaction (intraday)

As of publication time, IOVA shares were trading around $2.16 intraday, with the session range between $1.76–$2.41 (time stamp ~14:42 UTC). See live chart above.

What to watch next

Commercial ramp cadence. Watch activation and throughput at community ATCs, the InspiroGene distribution channel, and any additional real‑world data disclosures that might influence adoption curves. ^[21]
Manufacturing consolidation. The plan to centralize manufacturing at the Iovance Cell Therapy Center (iCTC) in early 2026 could be a margin lever; execution will matter. ^[22]
Ex‑U.S. milestones. Decisions or filings in the U.K., Australia (1H26), and Switzerland (2027), plus progress on the EMA path. ^[23]
NSCLC readouts. Additional IOV‑LUN‑202 data (planned 2026) and regulatory interactions that may set the pace toward a 2027 launch. ^[24]

Source notes (Nov. 6, 2025)

Company press release summarizing Q3 results, operations, and pipeline; webcast details and guidance. ^[25]
SEC Form 8‑K furnishing the Q3 press release. ^[26]
AP/Automated Insights earnings snapshot syndicated via Hearst (Times Union). ^[27]
Quiver Quantitative note on consensus beats/misses. ^[28]
Corporate presentation posted today (MarketScreener/PublicNow). ^[29]
Nov. 3 Iovance press release and independent coverage on IOV‑LUN‑202 interim data in NSCLC. ^[30]

Editor’s note: This article is for informational purposes only and does not constitute investment advice.

Iovance Biotherapeutics (IOVA) 🧬💉Strong Revenue, Extremely Undervalued! #millionaire #healthcare

Watch this video on YouTube.

References

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

View all

QuantumScape Extends Cash Runway to 2029, Refocusing on Licensing Growth
November 6, 2025, 12:42 PM EST. QuantumScape extended its liquidity runway to 2029, reinforcing its capital-light licensing strategy with partners like PowerCo, Murata and Corning. The company finished Q3 with about $1 billion in liquidity, aided by a $263.5 million at-the-market raise and tighter capex, guiding full-year capex to $30-$40 million and Adjusted EBITDA of $245-$260 million. The longer runway eases near-term fundraising pressure and supports development and industrialization, including scaling the Cobra separator process and advancing B1 cells. In Q3, QuantumScape invoiced $12.8 million in billings (not revenue), signaling early monetization and growing partner engagement. Risks include scaling performance, converting billings to recurring revenue, and securing future licensing deals. QS has outperformed peers and jumped ~242% YTD, though execution remains key.
Gogo (GOGO) Beats Q3 Earnings and Revenue Estimates Amid Mixed Outlook
November 6, 2025, 12:40 PM EST. Gogo (GOGO) reported Q3 earnings of $0.10 per share, topping the Zacks Consensus of $0.07 and marking a +42.86% surprise from the quarter. Revenue reached $223.59 million, slightly above the consensus by 0.2%, up from $100.53 million a year earlier. The company has surpassed EPS estimates in all four of the last four quarters. Management commentary on the upcoming earnings call will be crucial to gauge the sustainability of the move, as the stock has gained about 8.3% year-to-date versus the S&P 500's 15.6% gain. The current Zacks Rank remains #3 Hold, with near-term estimates for next quarter at $0.05 on $226.45 million in revenue and the current fiscal year at $0.30 on $905.94 million in revenue. Industry expectations for Wireless National remain a headwind.
C4 Therapeutics Q3 Loss Narrower, Revenue Beats Estimates; Zacks Rank Up (Buy)
November 6, 2025, 12:37 PM EST. C4 Therapeutics (CCCC) posted Q3 loss of $0.44 per share, better than the Zacks consensus of a $0.47 loss and up from $0.35 a year ago (adjusted for non-recurring items), delivering an earnings surprise of +6.38%. Revenue came in at $11.23 million, topping the consensus by 72.77% and down from $15.36 million a year earlier. The stock has shed about 34.2% this year, underperforming the S&P 500's 15.6% gain. On the outlook, near-term estimates were favorable going into the print, and C4 remains rated Zacks Rank #2 (Buy), with current consensus for the next quarter at -$0.29 on $9.5 million in revenues and -$1.46 on $29.7 million for the full year. Investors will await management commentary on the earnings call.
Microsoft Stock Split: Is a Dow-Linked Move Imminent?
November 6, 2025, 12:32 PM EST. Microsoft could be eyeing a stock split to ease its impact on the Dow Jones Industrial Average, a price-weighted index where MSFT wields outsized influence. With shares around the mid- to high-$400s, a split would keep the stock from creeping toward four figures and help maintain Dow eligibility among its 30 components. The case strengthens as Satya Nadella has steered the company into a cloud- and AI-driven growth era, lifting the stock since 2014 after the Ballmer era. Not since 2003 has MSFT split, and the market's structure-rather than the business itself-could motivate action before pricing milestones. Watch for signals from Microsoft leadership or Dow index committees.
Titan International Q3 Revenue Beats, but Q4 Guidance Falls Short
November 6, 2025, 12:31 PM EST. Titan International (NYSE:TWI) reported Q3 CY2025 revenue of $466.5 million, up 4.1% YoY and ahead of $458.9 million consensus (1.7% beat). GAAP EPS was -$0.04, vs -$0.03 expected, a $0.01 miss, while adjusted EBITDA reached $29.77 million on a 6.4% margin, an 11.1% beat. The company guided Q4 revenue at $397.5 million midpoint, below consensus of $420.7 million, and EBITDA at $10 million vs $16.48 million. Operating margin rose to 2.1% from 0.9% YoY; free cash flow margin slipped to 6.4% from 9.3%. Market cap is about $508 million. In a cyclical Agricultural Machinery backdrop, Titan faces growth headwinds but has shown some resilience in product demand.

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

What Iovance announced (Nov. 6, 2025)

Commercial execution: where growth is coming from

Pipeline update: lifileucel beyond melanoma

By the numbers (Q3 2025)

Market reaction (intraday)